Asia Pacific Gastric Cancer Diagnostic Procedure Market Forecast to 2028 - Regional Analysis - by Healthcare Providers (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Symptom Types (Symptomatic and

Asia Pacific Gastric Cancer Diagnostic Procedure Market Forecast to 2028- Regional Analysis- by Healthcare Providers (Diagnostic Laboratories, Hospitals, Cancer Research Institutes, Oncology Specialty Clinics, and Others), Symptom Types (Symptomatic and Asymptomatic), Body Fluid (Blood, Urine, Saliva, Stomach Wash/Gastric Juice, Tissue, and Others), Procedures (Endoscopic Procedures, Biopsy & Tissue Tests, Lab Tests, In-Vitro Diagnostic Tests, Imaging Tests, Molecular Diagnostics, Multiplexing Molecular Diagnostics & Immunoassays, and Others), Offerings [Instruments, Reagents & Consumables (Including Kits), and Services], Disease Indication (Early Gastric Cancer and Advanced Gastric Cancer Types) and country

The Asia Pacific gastric cancer diagnostic procedure market was valued at US$ 182.85 million in 2022 to US$ 349.33 million by 2028. It is estimated to grow at a CAGR of 11.4 % from 2022 to 2028.

Development of AI-Based Gastric Cancer Diagnostic Platforms to Bolster Asia Pacific Gastric Cancer Diagnostic Procedure Market During Forecast Period

Many players and research institutes operating in the gastric cancer diagnostics market are developing advanced products to expand their product portfolios and market shares. They invest significant amounts in R&D to develop advanced products. A few of the recent developments related to gastric cancer diagnostic platforms are mentioned below:

In February 2022, Mayo Clinic researchers used AI and informatics to discover a 32-gene signature that is a prognostic and predictive biomarker for patients suffering from gastric cancer. The study was published in the edition of Nature Communications. Thus, such developments in AI-based gastric cancer diagnostics are likely to introduce new trends in the gastric cancer diagnostic procedure market during the forecast period.

Asia Pacific Gastric Cancer Diagnostic Procedure Market Overview

The Asia Pacific gastric cancer diagnostic procedure market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2022 and India is expected to exhibit substantial growth in the market during the forecast period. The gastric cancer diagnostic procedure market growth in these countries is attributed to the increasing incidence of gastric cancer, growing awareness of the disease and its diagnosis, rising geriatric population, and surging prevalence of H. pylori infection.

Asia Pacific gastric cancer diagnostic procedure market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Gastric Cancer Diagnostic Procedure Market Segmentation

The Asia Pacific gastric cancer diagnostic procedure market is segmented into healthcare providers, symptom types, body fluid, procedures, offerings, disease indication, and country.

Based on healthcare providers, the market is segmented into diagnostic laboratories, hospitals, cancer research institutes, oncology specialty clinics, and others. The hospitals segment held the largest gastric cancer diagnostic procedure market share in 2022.

Based on body fluid, the Asia Pacific gastric cancer diagnostic procedure market is segmented into Blood, urine, saliva, stomach wash/gastric juice, tissue and others. Blood segment held largest Asia Pacific gastric cancer diagnostic procedure market share in 2022.

Based on offering, the Asia Pacific gastric cancer diagnostic procedure market is segmented into instruments, reagents & consumables, and services. Reagents & consumables segment held largest Asia Pacific gastric cancer diagnostic procedure market share in 2022.

Based on Diagnostic procedure, the Asia Pacific gastric cancer diagnostic procedure market is categorized into endoscopic procedure, biopsy and tissue tests, lab test, in-vitro diagnostic tests, imaging test, molecular diagnostics, multiplexing molecular diagnostics, immunoassay, and others. The imaging segment held largest Asia Pacific gastric cancer diagnostic procedure market share in 2022.

Based on disease condition, the Asia Pacific gastric cancer diagnostic procedure market is segmented into Early Gastric cancer and Gastric cancer advanced types. The Gastric cancer advanced type segment held larger Asia Pacific gastric cancer diagnostic procedure market share in 2022.

The Asia Pacific gastric cancer diagnostic procedure market, by country, has been categorized into China, India, Japan, South Korea, Australia, and Rest of Asia Pacific. China dominated the market in this region in 2022.

Atlas-Link Biotech Co Ltd; Bio-Rad Laboratories Inc; MiRXES Pte Ltd; Agilent Technologies Inc; F. Hoffmann-La Roche Ltd; bioMerieux SA; Thermo Fisher Scientific Inc; Illumina Inc; Vela Diagnostics Holding Pte Ltd; Myraid Genetics Inc. are the leading companies operating in the gastric cancer diagnostic procedure market in the Asia Pacific.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific Gastric Cancer Diagnostic Procedure Market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific trends and outlook coupled with the factors driving the Asia Pacific Gastric Cancer Diagnostic Procedure Market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution